Army enters partnership to develop Ebola vaccine
Yisheng U.S. is the wholly owned research subsidiary of Yisheng Biopharma Co. Ltd., a biopharmaceutical company that specializes in researching, developing, producing and selling vaccine products.
Both organizations will use a double-stranded, RNA-based Toll-Like Receptor 3 (TLR3) agonist adjuvant technology (PIKA). The ultimate goal is an Ebola vaccine that is safe, effective and potentially efficient in protecting people from other viruses as well.
"We are very pleased to have the USAMRIID join forces in exploring a more effective and safe Ebola Vaccine, which remains a significant unmet medical need,” Yi Zhang, the chairman of Yisheng Biopharma and the project leader of PIKA adjuvant technology, said. “Our PIKA adjuvant has exhibited broad potential to be a revolutionary innovation as a series of novel vaccines based on this technology are under pre-clinical and clinical investigations against rabies, HIV, Hepatitis-B, influenza, tuberculosis, and other viruses, which could significantly change the clinical practice paradigms against many human and animal virus infections. We are looking forward to updating the progress on these fronts in due course.”